<DOC>
	<DOC>NCT02958436</DOC>
	<brief_summary>The primary object of this study is to evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses of REGN3500 in healthy adult males and females</brief_summary>
	<brief_title>A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Body Mass Index&lt;/= 33 kg/m2 In good health based on medical history, physical examination, vital signs, and laboratory testing Normal electrocardiogram (ECG) and blood pressure Able to comply with clinic visits and studyrelated procedures Able to sign an informed consent Significant abnormalities in hematology, clinical chemistry, urinalysis, medical history Current smoker or recent history (within 3 months) History of tuberculosis, HIV, or hepatic disease Known sensitivity to doxycycline or other ingredients of study drug History of multiple/severe allergies Pregnant or breastfeeding women, or not currently using adequate contraception Participation in another investigational drug study within 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>REGN3500</keyword>
</DOC>